Insider trade

Director purchased ~$1.4K of KOD shares in the open market

Traded Sep 28, 2026 · Filed Sep 30, 2026

Kodiak SciencesKOD

~$1.4K
Approx. value · 17 sh @ $79.63: 1.61M
Holds after · shares reported

Why it stands out

A Kodiak Sciences director paid $1.4K out of pocket for Kodiak Sciences shares.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 28, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 30, 2026

DirectorIndirect holding<$25K

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$1,354

Shares × reported transaction price

Size band

<$25K

Rarity

Not enough history to judge

Confirmed open-market purchases by the same insider in the available history

Cluster activity

No other insider purchases within 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Timing vs results

46 days after results of Aug 13, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001193125-26-409118
Filed / recorded: Sep 30, 2026, 8:30 PM UTC
Added to OQRO: Oct 7, 2026, 1:55 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: Kodiak Sciences Inc.
Issuer CIK: 1468748
Ticker: KOD
Reporting person: BAKER BROS. ADVISORS LP
Relationship: Director, 10% owner
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 28, 2026
Transaction code: P
Shares / units: 17
Price per share: $79.63
Acquired / disposed: Acquired (A)
Shares owned after: 1,606,443
Ownership form: Indirect — See Footnotes
Amendment: No

Footnotes from the filing

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.